Friday, July 10, 2026
🇺🇸 FDA

pharma · Diabetes · Congenital Bleeding Disorder

Novo Nordisk A/S

Novo Nordisk A/S trial registry — 51 ClinicalTrials.gov studies with program phase, status, and indication context.

Website Investor relations
Novo Alle, Bagsværd, 2880, DK HQ
1923 Founded
63,033 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Novo Alle, Bagsværd, 2880, DK
Founded
1923
Employees
63,033
Programs
40
Drugs
46
Patents
0
Official website ↗ All projects Drug pipeline News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Trials

Novo Nordisk A/S clinical trials

Registry index of 51 ClinicalTrials.gov studies linked to Novo Nordisk A/S programs — each row shows trial ID, program name, phase, status, and indication.

Novo Nordisk A/S trial registry — 51 ClinicalTrials.gov studies with program phase, status, and indication context.

Recent trial activity

8 updates

Latest clinical program signals indexed for Novo Nordisk A/S.

  1. CHRD 2419 — Phase 3

    Clinical update

  2. KCT02/2023-SATELLITE — Approved

    Clinical update

  3. KCT23/2022-ZOOM-IN — Approved

    Clinical update

  4. KCT10/2022-LEASH — Approved

    Clinical update

  5. EF-41/KEYNOTE D58 — Phase 3

    Clinical update

  6. turoctocog alfa pegol — Phase 3

    Clinical update

  7. turoctocog alfa — Approved

    Clinical update

  8. Oral semaglutide — Phase 3

    Clinical update

Trial registry

51 studies
  7. 2024-516793-30-00

    UVEDOSE 100 000 UI, solution buvable en ampoule

    Phase 3 active small_molecule

    Thyroidectomy is a common operation. Transient postoperative hypocalcemia is the main complication, resulting in clinical discomfort for patients, longer hospital stays and increased perioperative cost. Cholecalciferol is used to supplement vitamin D deficiency. We suppose that systematic pre-operative supplementation with cholecalciferol would allow a faster and more appropriate response to post-operative hypocalcemia

    CTIS ↗

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.